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OBJECTIVES: To evaluate the impact of the first selective 
cannabinoid type 1 (CB1) receptor blocker, rimonabant, developed 
for the management of cardiometabolic risk factors, on 
health related quality of life (HRQOL) in overweight/obese 
patients with type 2 diabetes. METHODS: A total of 1045patients  
with type 2 diabetes were randomized in a double-blind 
trial and received either rimonabant 5mg, 20 mg or placebo. 
Patients completed the Impact of Weight on Quality of Life-Lite 
(IWQOL-Lite), a validated 31-item questionnaire specifically 
designed for HRQOL assessment in obesity, and reported days 
missed from work at baseline and every 3-months up to 1 year. 
Analyses were performed on mean score changes from baseline 
to 1 year in the ITT population. Clinical meaningfulness was 
assessed using the Effect Size (ES) method, which is a measure 
of change over time that takes into account the variability within 
the sample at baseline. RESULTS: At 1 year, patients administered 
rimonabant 20 mg once daily (N = 339) reported significantly 
greater improvement (p < 0.001, and p = 0.03 for Work) 
in IWQOL-Lite total score and 3 out of 5 domains (Physical 
Function, Self-esteem and Work) than patients in the placebo 
group (N = 348) (no significant change in Sexual Life and Public 
Distress). These improvements were clinically meaningful (ES > 
0.2). Also, there was a trend to fewer days missed from work 
reported by patients on rimonabant 20 mg (720 days) compared 
with those on placebo (1242 days) over the study period (p = 
0.2 based on the number of patients with at least 1 day missed 
from work). CONCLUSIONS: HRQOL results showed both a 
statistically significant and clinically meaningful improvement in 
total score and also several domains (Physical Function, Selfesteem 
and Work) of the IWQOL-Lite questionnaire, with 
rimonabant versus placebo after a once daily administration of 
20 mg rimonabant in this population of overweight/obese 
patients with diabetes. 
